Literature DB >> 23518210

Time trends in survival from cancer of unknown primary: small steps forward.

M Riihimäki1, A Hemminki, K Sundquist, K Hemminki.   

Abstract

BACKGROUND: Cancer of unknown primary (CUP) is a fatal cancer for which incidence trends have changed but detailed survival trends remain unexplored. These could point out successful diagnostic and therapeutic approaches. We investigate survival trends in CUP according to histology, locations of metastases and site-specific causes of death. PATIENTS AND METHODS: A total of 20,523 CUP patients with nodal and extranodal metastases were identified from the Swedish Cancer Registry. Hazard ratios (HRs) were estimated, comparing three different time periods (1987-1993, 1994-2000 and 2001-2008) with respect to histological subtype, CUP location and the cause of death.
RESULTS: Survival for patients with CUP increased over the study period (HR=0.91 [95% confidence interval (CI): 0.78-0.84], p<0.001 for trend). Adenocarcinoma was the only histology associated with increased survival (0.78 [0.74-0.82], p<0.001 for trend). Survival was improved most clearly for CUP of the pelvis (0.55 [0.36-0.83]), peritoneum (0.58 [0.53-0.65]) and nervous system (0.46 [0.29-0.72]). Survival improved substantially in patients with ovarian (0.57 [0.46-0.70]), peritoneal (0.39 [0.24-0.65]) and biliary system cancers (0.67 [0.52-0.87]). Kaplan-Meier curves showed significant survival gains for all CUP and adenocarcinoma patients (p<0.001).
CONCLUSIONS: Over time, survival for patients with CUP increased for adenocarcinoma and for CUP of the pelvis, peritoneum and nervous system. Survival trends in CUP may be related to (1) similar trends in other common metastatic tumours, particularly pancreatic and hepatobiliary cancers, which are common 'hidden' primaries for CUP, (2) earlier detection and (3) advances in the management of metastatic cancers. The improvement in survival at specific locations suggests true therapeutic gains.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23518210     DOI: 10.1016/j.ejca.2013.02.022

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  13 in total

Review 1.  Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.

Authors:  Sebastián Moran; Anna Martinez-Cardús; Stergios Boussios; Manel Esteller
Journal:  Nat Rev Clin Oncol       Date:  2017-07-04       Impact factor: 66.675

2.  Simplified/Same Day(s)-GOLF as First-line Treatment of Metastatic Carcinoma of Unknown Primary (CUP), Suggestive of Pancreatobiliary Tumors.

Authors:  Muhammad Wasif Saif; Komal Wasif; Martin D Goodman; Sanjay Hegde; Mark Sterling; Robert Yacavone; Sunny Jaiswal; Barbara Weinstein; Kevin Daly; Valerie Relias
Journal:  JOP       Date:  2019-11

3.  Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins.

Authors:  Yihong Wang; Lauren Ende Schwartz; Derek Anderson; Ming-Tseh Lin; Lisa Haley; Ren-Chin Wu; Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Oncotarget       Date:  2015-09-08

4.  Location of metastases in cancer of unknown primary are not random and signal familial clustering.

Authors:  Kari Hemminki; Kristina Sundquist; Jan Sundquist; Akseli Hemminki; Jianguang Ji
Journal:  Sci Rep       Date:  2016-03-09       Impact factor: 4.379

5.  Are we ready for routine precision medicine? Highlights from the Milan Summit on Precision Medicine, Milan, Italy, 8-9 February 2018.

Authors:  Luca Mazzarella
Journal:  Ecancermedicalscience       Date:  2018-03-05

Review 6.  2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary.

Authors:  F Losa; L Iglesias; M Pané; J Sanz; B Nieto; V Fusté; L de la Cruz-Merino; Á Concha; C Balañá; X Matías-Guiu
Journal:  Clin Transl Oncol       Date:  2018-05-28       Impact factor: 3.405

7.  Carcinoma of Unknown Primary in a Patient With Lynch Syndrome.

Authors:  Nat C Jones; Jacob J Adashek; Bassam Ayoub
Journal:  Cureus       Date:  2021-06-16

8.  GyneScan: an improved online paradigm for screening of ovarian cancer via tissue characterization.

Authors:  U Rajendra Acharya; S Vinitha Sree; Sanjeev Kulshreshtha; Filippo Molinari; Joel En Wei Koh; Luca Saba; Jasjit S Suri
Journal:  Technol Cancer Res Treat       Date:  2013-12-06

9.  A case of occult intrahepatic cholangiocarcinoma diagnosed by autopsy.

Authors:  Eri Oda; Daisuke Hashimoto; Yuko Shiomi; Koji Ohnishi; Hiromitsu Hayashi; Akira Chikamoto; Motohiro Takeya; Hideo Baba
Journal:  Surg Case Rep       Date:  2015-10-14

10.  Age-Dependent Metastatic Spread and Survival: Cancer of Unknown Primary as a Model.

Authors:  Kari Hemminki; Nicholas Pavlidis; Konstantinos K Tsilidis; Kristina Sundquist; Jianguang Ji
Journal:  Sci Rep       Date:  2016-03-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.